Insmed Inc. will seek accelerated approval for amikacin liposome inhalation suspension (ALIS) after the drug candidate formerly known as Arikayce eliminated the bacterial evidence of a rare lung disease in a Phase III clinical trial, pursuing a path originally shot down by the US FDA in 2014.
Bridgewater, NJ-based Insmed's stock price more than doubled on Sept. 5 – rising 119.6% to close at $26.99 – after...






